Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3333585 | Seminars in Hematology | 2009 | 8 Pages |
Abstract
Multiple myeloma (MM) patients have a highly variable disease course and survival varies from a few months to more than 10 years. Numerous prognostic factors have been identified, including age, performance status (PS), serum albumin, β2-microglobulin (β2M), lactate dehydrogenase (LDH), renal function, genetic factors, and serum free light chains (sFLCs) or their ratio (sFLCR). Several models have been built to separate patients into various risk groups with different outcomes. Staging systems need to be simple, accurate, and readily available in order to effectively guide treatment decisions now that effective treatments exist that prolong survival. The International Staging System (ISS) is currently in use; it is highly prognostic but presents some limitations. We suggest that the ISS prognostic potential could be improved with the addition of sFLCR and eventually LDH.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Marie-Christine Kyrtsonis, Dimitrios Maltezas, Tatiana Tzenou, Efstathios Koulieris, Arthur R. Bradwell,